Franco Carmen, Martínez Virginia, Allamand Juan Pablo, Medina Francisco, Glasinovic Andrea, Osorio Miren, Schachter Dina
Unidad de Anatomía Patológica, Clínica Santa María, Santiago, Chile.
Appl Immunohistochem Mol Morphol. 2009 May;17(3):211-5. doi: 10.1097/PAI.0b013e31818935a9.
Fine-needle aspiration biopsy (FNAB) is the most accurate study in the preoperative evaluation of patients with thyroid nodules. However, one of its limitations is the indeterminate or suspicious sample which accounts for 15% to 25% of the cases; both follicular and Hürthle cell neoplasms are included in this category.
To assess the accuracy of the molecular markers HBME-1 and galectin-3 in suspicious or indeterminate FNABs comparing the results with the histologic diagnosis of the thyroidectomy specimen.
A prospective study was carried out at 2 Health Centers in Santiago, Chile. From July 2003 to March 2008, 418 FNABs with indeterminate or suspicious diagnosis were immunostained with HBME-1 and galectin-3. Immunohistochemistry was performed on a clot obtained by FNAB, which was formalin-fixed and paraffin-embedded. The results were matched with the definitive histologic diagnosis of the thyroidectomy specimen.
Of 418 patients submitted to FNAB with immunohistochemistry, 138 patients underwent surgery. The sensitivity, specificity, positive predictive value, and negative predictive value were 78.67%, 84.13%, 85.51%, and 76.81%, respectively, for HBME-1 and 82.67%, 80.95%, 83.78%, and 79.69%, respectively, for galectin-3. Whereas the results for both markers combined were 94.74%, 75.81%, 82.76%, and 92.16%.
With the combined use of HBME-1 and galectin-3 in indeterminate FNABs, a 10% increase in sensitivity is achieved. These markers show excellent sensitivity and specificity and may improve patient's selection for surgery.
细针穿刺活检(FNAB)是甲状腺结节患者术前评估中最准确的检查方法。然而,其局限性之一是不确定或可疑样本,占病例的15%至25%;滤泡性肿瘤和许特莱细胞肿瘤均属于此类。
评估分子标志物HBME-1和半乳糖凝集素-3在可疑或不确定FNAB中的准确性,并将结果与甲状腺切除标本的组织学诊断进行比较。
在智利圣地亚哥的2个健康中心进行了一项前瞻性研究。2003年7月至2008年3月,对418例诊断为不确定或可疑的FNAB进行了HBME-1和半乳糖凝集素-3免疫染色。免疫组织化学在通过FNAB获得的凝块上进行,该凝块经福尔马林固定和石蜡包埋。结果与甲状腺切除标本的最终组织学诊断进行匹配。
418例接受免疫组织化学FNAB的患者中,138例接受了手术。HBME-1的敏感性、特异性、阳性预测值和阴性预测值分别为78.67%、84.13%、85.51%和76.81%,半乳糖凝集素-3分别为82.67%、80.95%、83.78%和79.69%。而两种标志物联合使用的结果分别为94.74%、75.81%、82.76%和92.16%。
在不确定的FNAB中联合使用HBME-1和半乳糖凝集素-3,敏感性提高了10%。这些标志物显示出优异的敏感性和特异性,可能改善手术患者的选择。